Comment from Insmed Incorporated

Summary: Insmed Incorporated provides detailed feedback on the proposed Expedited Investigational New Drug Pilot Program, offering specific recommendations on QRI qualifications, conflict of interest mitigations, and success metrics. While they express concerns about potential resource burdens and the need for clear FDA oversight, they generally support the initiative as a means to accelerate Phase 1 FIH study initiation.